TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04757948

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupuncture of acupoints P-6 and St-36

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TENS
Description: TENS of acupoints P-6 and St-36

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham-TENS
Description: Sham-TENS of acupoints P-6 and St-36
Study: NCT00289198

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF
Description: fluticasone furoate 110 μg nasal spray

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo nasal spray
Study: NCT02270723

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5% Human Albumin  Behring
Description: Intravenous infusion of 5% Human Albumin during major surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lactated Ringer
Description: Intravenous infusion of Lactated Ringer during major surgery
Study: NCT02804750

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CORT125134

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CORT125134
Study: NCT03156738

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-2990
Description: Subjects will receive a single IV dose of MT-2990

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-2990
Description: Subjects will receive a single IV dose of MT-2990

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-2990
Description: Subjects will receive a single IV dose of MT-2990

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will receive a single IV dose of placebo
Study: NCT03194191

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture needles
Description: The patient will be in a semi recumbent position during needle penetration. Duration of needle insertion: 30 minutes

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Acupuncture needles
Description: The patient will be in a semi recumbent position during needle penetration. Duration of needle insertion: 30 minutes
Study: NCT01478841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: polyphenol
Description: 2 capsules of 0.5 gram to be taken at the beginning of breakfast and dinner (2g/day) fructose : dose of 3 g/kg/day from D57 to D62 in the form of a 20% solution taken during the three main meals

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 2 capsules of 0.5 gram to be taken at the beginning of breakfast and dinner (2g/day) fructose : dose of 3 g/kg/day from D57 to D62 in the form of a 20% solution taken during the three main meals
Study: NCT00504790

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK923295
Description: anti-mitotic compound
Study: NCT03730077

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-FMISO
Description: 18F-FMISO PET/CT
Study: NCT03156738

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will receive a single IV dose of placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will receive a single IV dose of placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will receive a single IV dose of placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will receive a single IV dose of placebo
Study: NCT03936699

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Nerve Stimulator (TENS)
Description: The Elira wearable patch system is a Radio Frequency (RF) coupled, wearable transcutaneous electrical nerve stimulator (TENS) device controlled via Bluetooth by a smart phone unit running a custom application which directs therapy from the patch within safe limits set by a clinician and also includes a weight loss diary.~Behavioral: Diet \& Exercise Subjects to be instructed on a healthy 1200 calorie diet.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diet & Exercise
Description: Subjects to be instructed on a healthy 1200 calorie diet.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet & Exercise
Description: Subjects to be instructed on a healthy 1200 calorie diet.
Study: NCT05118100

Intervention type: DRUG
Intervention: Clearfil Protect Bond
Description: An adhesive is used routinely when placing resin composite restorations. This group receives a commercially available adhesive containing an antibacterial monomer (MDPB)

Intervention type: DRUG
Intervention: Clearfil SE Bond
Description: An adhesive is used routinely when placing resin composite restorations. This group receives a commercially available adhesive.
Study: NCT00068107

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Replagal
Description: enzyme replacement therapy
Study: NCT01419184

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daptomycin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin
Study: NCT02662816

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Proton magnetic resonance spectroscopy (1H MRS)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: a protein rich breakfast at home

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: a protein rich lunch at the Clinical Investigation Center
Study: NCT04417075

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Impacto (Mobile App)
Description: This is the mobile app to be developed and evaluated in this project. It is designed for Spanish-speaking, Latinx smokers with high anxiety sensitivity and will be built for the Android platform. The app will include components to address and remediate anxiety sensitivity, as well as having smoking cessation components.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dejar de Fumar Asistente (Mobile App)
Description: Dejar de Fumar Asistente (English version called: Quit Tracker: Stop Smoking) is a popular, free third party mobile application aimed at helping smokers quit smoking. This is the mobile app that will serve as the control condition in evaluating the efficacy of Impacto. This mobile app is well established as a smoking cessation app for Spanish-speaking, Latinx smokers. The app includes smoking cessation components but does not have a specific emphasis on anxiety sensitivity.
Study: NCT01098877

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PF-04634817 Placebo
Description: Oral solution, placebo, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04634817
Description: Oral solution, 1mg, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04634817
Description: Oral solution, 3mg, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04634817
Description: Oral solution, 10mg, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04634817
Description: Oral solution, 30mg, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04634817
Description: Oral solution, 100mg, single dose
Study: NCT03711058

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copanlisib
Description: Copanlisib will be administered as a 60 minute IV infusion (-5min/+10min) at a dose of 45 mg - 60 mg IV. Copanlisib will be administered once a week (days 1, 8, and 15 or Day 1 and Day 15 of each 28 day cycle).~Drug: 45 or 60 mg IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copanlisib
Description: Copanlisib will be administered as a 60 minute IV infusion (-5min/+10min) at a dose of 45 mg - 60 mg IV. Copanlisib will be administered once a week (days 1, 8, and 15 or Day 1 and Day 15 of each 28 day cycle).~Drug: 45 or 60 mg IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copanlisib
Description: Copanlisib will be administered as a 60 minute IV infusion (-5min/+10min) at a dose of 45 mg - 60 mg IV. Copanlisib will be administered once a week (days 1, 8, and 15 or Day 1 and Day 15 of each 28 day cycle).~Drug: 45 or 60 mg IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 480 mg will be administered as a 30 minute IV infusion (-5min/+10min) on Day 1 of each 28 day cycle.~Drug: 480 mg IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 480 mg will be administered as a 30 minute IV infusion (-5min/+10min) on Day 1 of each 28 day cycle.~Drug: 480 mg IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 480 mg will be administered as a 30 minute IV infusion (-5min/+10min) on Day 1 of each 28 day cycle.~Drug: 480 mg IV
Study: NCT02661958

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S6G5T-3
Description: once a day topical cream

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S6G5T-1
Description: once a day topical cream

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S6G5T-5
Description: once a day topical cream

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S6G5T-6
Description: once a day topical cream

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S6G5T-7
Description: once a day topical cream
Study: NCT01098877

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04634817
Description: Oral solution, 300mg, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04634817
Description: Oral solution, 600mg, single dose
Study: NCT02661958

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: S6G5T-8
Description: once a day topical cream
Study: NCT01187888

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rasagiline
Description: tablet once daily 1 mg 1 year

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar pill
Description: tablet once daily one year
Study: NCT01327014

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XueZhiKang (XZK), a botanic product with multiple components
Description: 4 capsules of study drug twice a day for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XueZhiKang (XZK), a botanic product with multiple components
Description: 4 capsules of study drug twice a day for 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 capsules twice a day for 12 weeks.
Study: NCT02099409

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FLORENCED2
Description: FLORENCED2 device ensures the closed loop between Freestyle Navigator II and the DANA DIABECARE R

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FLORENCED2
Description: FLORENCED2 device ensures the closed loop between Freestyle Navigator II and the DANA DIABECARE R
Study: NCT02434991

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Barostat
Description: * During this study, the investigators will ask you to fill out questionnaires about your swallowing, chest pain, and heartburn. The investigators hope the patient will answer all of the questions, but patients can skip any questions they do not want to answer. The questionnaires will take about 15 minutes to complete.~* A urine pregnancy test for females of childbearing years.~* Patients will be asked to fast overnight (nothing to eat or drink for 8 hours) prior to the barostat test.~* At this point healthy controls have completed the study.~* Patients with achalasia will then undergo treatment for achalasia at the discretion of the primary clinician managing their case.~* Patients will be contacted to complete a phone survey 3 \& 6 months and 2 \& 4 years after treatment.
Study: NCT00539084

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MicronJet
Description: The MicronJet is a microneedle injection device designed for intradermal delivery of drugs (i.e. delivery into the layers of the skin). In this study the MicronJet will be used to inject Lidocaine or Saline.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: MicronJet
Description: The MicronJet is a microneedle injection device designed for intradermal delivery of drugs (i.e. delivery into the layers of the skin). In this study the MicronJet will be used to inject Lidocaine or Saline.
Study: NCT00074425

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BufferGel
Description: Participants will be given single-use, prefilled applicators of gel and will be instructed to apply one dose of BufferGel intravaginally up to 60 minutes before each vaginal intercourse while in the study.
Study: NCT01098877

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04634817
Description: Oral solution, 900mg, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04634817
Description: Oral solution, up to 900mg, single dose after food

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PF-04634817 Placebo
Description: Oral solution, placebo, single dose after food
Study: NCT00074425

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRO 2000/5 Gel
Description: Participants will be given single-use, prefilled applicators of gel and will be instructed to apply one dose of PRO 2000/5 Gel intravaginally up to 60 minutes before each vaginal intercourse while in the study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo gel
Description: Participants will be given single-use, prefilled applicators of gel and will be instructed to apply one dose of PRO 2000/5 Gel intravaginally up to 60 minutes before each vaginal intercourse while in the study.
Study: NCT04393571

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile application
Description: telemedicine is used to overcome distance when patients must travel to receive specialized care. We depend on the available, widely used smartphones via a mobile application to conduct follow up data as regard to patient quality of life and comparing this to conventional follow up visits and whether it help to obtain a complete follow up data

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile application
Description: telemedicine is used to overcome distance when patients must travel to receive specialized care. We depend on the available, widely used smartphones via a mobile application to conduct follow up data as regard to patient quality of life and comparing this to conventional follow up visits and whether it help to obtain a complete follow up data
Study: NCT00249405

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citalopram + MI
Description: 14-week citalopram treatment + Motivational Interview (MI) and 9 brief sessions of a manual-guided Compliance Enhancement Therapy; post-treatment follow-up assessments will be conducted at 4, 12 and 24 weeks.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + MI
Description: placebo + single Motivational Interview (MI) and 9 brief sessions of a manual-guided Compliance Enhancement Therapy; post-treatment follow-up assessments will be conducted at 4, 12 and 24 weeks.
Study: NCT04955054

Intervention type: DIAGNOSTIC_TEST
Intervention: diagnose
Description: Patients from UAP and AMI meet the criteria of UAP or STEMI.

Intervention type: DIAGNOSTIC_TEST
Intervention: diagnose
Description: Patients from UAP and AMI meet the criteria of UAP or STEMI.
Study: NCT04810832

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evoked related potentials
Description: Evoked related potentials are performed for each patient during each paradigm (neutral voice and expressive voices):~* with scalp electrodes in the department of neurophysiology~* with intracranial electrodes in the department of neurosurgery.
Study: NCT01456156

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: postoperative radiotherapy
Description: IMRT or 3DCRT, 50-60Gy to the tumor bed
Study: NCT03397134

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo administered as a single dose once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo administered as a single dose once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Roluperidone 32 mg
Description: Roluperidone administered as a single dose once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roluperidone 32 mg
Description: Roluperidone administered as a single dose once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Roluperidone 64 mg
Description: Roluperidone administered as a single dose once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roluperidone 64 mg
Description: Roluperidone administered as a single dose once daily
Study: NCT02757443

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phosphocreatine sodium tetrahydrate after anaesthesia induction
Description: after anaesthesia induction 2 g of Phosphocreatine (PCr) prepared in 50 mL of glucose 5% during 30 min intravenous (IV)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 5% Glucose after anaesthesia induction
Description: after anaesthesia induction 50 mL of glucose 5% IV delivered by an identical infusion pump during 30 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phosphocreatine sodium tetrahydrate added to cardioplegia
Description: together with cardioplegia 2.5 g of PCr prepared in 50 mL of glucose 5% and added to every 1 L of cardioplegic solution (Custodiol, Dr. F. KOHLER CHEMIE, GmbH, Germany; concentration = 10 mmol/L)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 5% Glucose
Description: together with cardioplegia 50 mL of glucose 5% is added in every 1 L of cardioplegic solution (Custodiol, Dr. F. KOHLER CHEMIE, GmbH, Germany)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phosphocreatine sodium tetrahydrate after heart recovery
Description: immediately after heart recovery (spontaneous or paced myocardium contraction) after aorta declamping 2 g of PCr prepared in 50 mL of glucose 5% during 30 min IV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 5% Glucose after heart recovery
Description: immediately after heart recovery (spontaneous or paced myocardium contraction) after aorta declamping 50 mL of glucose 5% IV delivered by an identical infusion pump during 30 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phosphocreatine sodium tetrahydrate after ICU admission
Description: immediately after ICU admission 4 g of PCr in 100 mL of glucose 5% during 60 min IV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 5% Glucose after ICU admission
Description: immediately after ICU admission 100 mL of glucose 5% IV delivered by an identical infusion pump during 60 minutes
Study: NCT03287674

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 60 mg/kg is administered i.v. on day -7 and day -6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 25 mg/m2 is administered on day -5 to day -1.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TIL infusion
Description: The maximum number of expanded TILs are infused over 30-45 minutes on day 0.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: Interleukin-2 is administered as a daily low-dose subcutaneous injection of 2 MIU for a total of 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: One dose of Ipilimumab 3 mg/kg is administered 14 days prior to surgical removal of tumor tissue for TIL expansion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 3 mg/kg is administered on day -2 before TIL infusion and every 2 weeks for a total of 4 doses.
Study: NCT05792644

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: crizotinib for rearrangement-negative, high phosphorylated ALK patients
Description: Patients with positive ALK phosphorylation expression were treated with crizotinib 250 mg/day orally. A treatment cycle was defined as 30 days of once-daily crizotinib treatment. Treatment with crizotinib continued until the patient experienced unacceptable toxicity, was pregnant, or started new cancer therapy.
Study: NCT00934947

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Description: 40 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: sugar pill

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propanolol
Description: 120 mg twice per day
Study: NCT05985213

Intervention type: OTHER
Intervention: data collection and follow-up
Description: Main measures and data collection methods:~1. Recording of baseline demographic and clinical information of the participants.~2. Multimodal magnetic resonance imaging~3. blood pressure variability.~4. neuropsychological testing~5. Blood samples collection
Study: NCT01224821

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tositumomab (Anti-B1 Antibody) and Iodine-131 Tositumomab
Description: Patients receive a dosimetric dose consisting of 450 milligrams (mg) of unlabeled tositumomab (TST, Anti-B1 Antibody) intravenously (IV) followed by 5 milliCurie (mCi) of Iodine I 131 TST IV. Serial whole body sodium iodide probe scintillation counts and whole body conjugate view gamma camera scans obtained approximately 1 hour after administration and then daily for the next 7 days were used to determine the radioactive clearance and the dose of iodine I 131 TST required to deliver a 75 centigray (cGy) therapeutic dose. The therapeutic dose was administered 7-14 days after the dosimetric dose and consisted of TST 450 mg and an activity of Iodine 131 calculated to deliver 75 cGy or 65 cGy of total body irradiation, depending on platelet count, and 35 mg TST.
Study: NCT02710435

Intervention type: DEVICE
Intervention: Reducer System
Description: An aid in the management of chronic refractory angina pectoris

Intervention type: DEVICE
Intervention: Reducer System
Description: An aid in the management of chronic refractory angina pectoris

Intervention type: DEVICE
Intervention: Reducer System
Description: An aid in the management of chronic refractory angina pectoris
Study: NCT04133896

Intervention type: DIAGNOSTIC_TEST
Intervention: IL-6, Clusterin, Irisin Level
Description: Blood samples to determine levels of Circulating IL-6, Clusterin and Irisin

Intervention type: DIAGNOSTIC_TEST
Intervention: IL-6, Clusterin, Irisin Level
Description: Blood samples to determine levels of Circulating IL-6, Clusterin and Irisin

Intervention type: DIAGNOSTIC_TEST
Intervention: IL-6, Clusterin, Irisin Level
Description: Blood samples to determine levels of Circulating IL-6, Clusterin and Irisin

Intervention type: DIAGNOSTIC_TEST
Intervention: IL-6, Clusterin, Irisin Level
Description: Blood samples to determine levels of Circulating IL-6, Clusterin and Irisin

Intervention type: DIAGNOSTIC_TEST
Intervention: IL-6, Clusterin, Irisin Level
Description: Blood samples to determine levels of Circulating IL-6, Clusterin and Irisin

Intervention type: DIAGNOSTIC_TEST
Intervention: IL-6, Clusterin, Irisin Level
Description: Blood samples to determine levels of Circulating IL-6, Clusterin and Irisin

Intervention type: DIAGNOSTIC_TEST
Intervention: IL-6, Clusterin, Irisin Level
Description: Blood samples to determine levels of Circulating IL-6, Clusterin and Irisin

Intervention type: DIAGNOSTIC_TEST
Intervention: IL-6, Clusterin, Irisin Level
Description: Blood samples to determine levels of Circulating IL-6, Clusterin and Irisin